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The Modification of Diet in Renal Disease (MDRD)
Study randomized 840 patients, with nondiabetic stage 3
to 4 chronic kidney disease to a blood pressure of less than
140/90 mmHg or to a blood pressure of 125/75 mmHg
(1,2). The blood pressures achieved in this study were
133/80 mmHg versus 126/77 mmHg. The mean followup was 2.2 years. This study did not show a difference in
death and in kidney failure between the 2 blood pressure
groups. However, this study showed that in patients with
proteinuria greater than 1,000 mg per day, the lower blood
pressure group had a significant slower rate of decline in
glomerular filtration rate (1,2).
The Ramipril Efficacy in Nephropathy (REIN-2)
trial randomized 338 patients with nondiabetic stage 3
to 4 chronic kidney disease to a blood pressure of less
than 140/90 mmHg or to a blood pressure of less than
130/80 mmHg (3). The blood pressures achieved in this
study were 134/82 mmHg versus 130/80 mmHg. The
median follow-up was 1.6 years. This study did not show
a difference in death and in kidney failure between the
2 blood pressure groups (3).
The African American Study of Kidney Disease
(AASK) trial randomized 1,094 patients with nondiabetic
hypertensive stage 3 chronic kidney disease to a blood
pressure of less than 140/90 mmHg or to a blood pressure
of 125/75 mmHg (4,5). The blood pressures achieved
in this study were 141/86 versus 130/78 mmHg. The
median follow-up was 3.8 years. This study did not show a
difference in death, end-stage renal disease, or a reduction
in glomerular filtration rate of 50% or more between the
2 blood pressure groups (4). However, a subanalysis showed
a reduction in this primary endpoint in patients with
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proteinuria with a protein-to-creatinine ratio of more than
0.22 (5).
A meta-analysis of 2,272 patients with nondiabetic
chronic kidney disease in the AASK, REIN-2, and MDRD
studies found that the lower blood pressure achieved in
these 3 trials of 126–130/77–80 mmHg did not improve
clinical outcomes (6). However, this meta-analysis suggested
that the lower blood pressure target may be beneficial
in patients with chronic kidney disease with proteinuria
greater than 300 to 1,000 mg daily (6).
On the basis of the available data, the International
Society of Nephrology 2012 guidelines for treatment of
blood pressure in patients with non-dialysis-dependent
chronic kidney disease state that hypertensive patients with
chronic kidney disease and albuminuria less than 30 mg
per 24 hours should have their blood pressure lowered to
less than 140/90 mmHg (7,8). If albuminuria greater than
30 mg per 24 hours is present, the blood pressure may be
lowered to less than 130 mm/80 mmHg with a class II D
indication (7,8).
A meta-analysis reported in 2013 of 11 randomized trials
in 9287 patients with chronic kidney disease and 1,264
kidney failure events showed that intensive blood pressure
lowering reduced the incidence of kidney failure 27% but
not in patients who did not have baseline proteinuria (9).
Another meta-analysis reported in 2013 included
26 randomized trials with 30,295 patients with chronic
kidney disease (10). This study showed that compared with
placebo, blood pressure lowering reduced the incidence of
major cardiovascular events by approximately a sixth per
5 mmHg reduction in systolic blood pressure (10).
A meta-analysis reported in 2016 included 19 randomized
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trials of 44,989 patients with and without chronic kidney
disease in whom 2496 major cardiovascular events occurred
during a mean follow-up of 3.8 years (11). Compared
to a blood pressure achieved of 140/81, more intensive
blood pressure lowering to an achieved blood pressure of
133/76 mmHg reduced major cardiovascular events 14%.
Absolute reductions in major cardiovascular events were
greatest in trials in which all enrolled patients had vascular
disease, chronic kidney disease, or diabetes mellitus (11).
The most important randomized, antihypertensive
clinical trial comparing a systolic blood pressure goal of
less than 120 mmHg with a systolic blood pressure goal of
less than 140 mmHg which included patients with chronic
kidney disease is the Systolic Blood Pressure Intervention
Trial (SPRINT) (12,13). This trial included 9,361 patients
aged 50 years and older with a systolic blood pressure of
130 mmHg or higher and an increased cardiovascular risk
but without diabetes mellitus, prior stroke, heart failure, or
a left ventricular ejection fraction below 35%. The mean
age was 67.9 years, 28.3% of patients were aged 75 years
and older, and 28.4% of patients had chronic kidney disease
with a baseline estimated glomerular filtration rate between
20 to 59 mL/min/1.73 m2 Automated blood pressures were
obtained in this study. The mean achieved systolic blood
pressures at 1 year were 121.4 mmHg in the intensive
treatment group versus 136.2 mmHg in the standard
treatment group. The median follow-up was 3.26 years.
The primary composite endpoint was cardiovascular death,
myocardial infarction, other acute coronary syndromes,
heart failure, or stroke. At follow-up, intensive treatment
of blood pressure reduced the primary outcome 25% and
all-cause mortality 27% in the entire group (12) and the
primary outcome 34% and all-cause mortality 33% in the
group aged 75 years and older (13). In the entire group of
patients with chronic kidney disease, all-cause mortality
was reduced 27% from 7.22% with standard blood
pressure treatment to 5.26% with intensive blood pressure
treatment (12). The composite renal outcome of first
occurrence of a reduction in estimated glomerular filtration
rate of 50% or more, long-term dialysis, or kidney
transplantation was 1.1% in both blood pressure treatment
groups. Intensive blood pressure treatment was also
beneficial in patients with chronic kidney disease who were
aged 75 years and older including those with frailty or the
slowest gait speed (13).
On the basis of the data from SPRINT, the 2016
Canadian hypertension guidelines recommended lowering
the systolic blood pressure to 120 mmHg or lower in
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selected high-risk patients such as those with chronic
kidney disease with an estimated glomerular filtration rate
between 20 to 59 mL/min/1.73 m 2 (14,15). Automated
blood pressures must be obtained in these patients. I concur
with automated blood pressure measurements since they are
more accurate. On the basis of the current available data, I
favor lowering the blood pressure in patients with chronic
kidney disease to less than 130/80 mmHg.
Angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, beta blockers, calcium channel
blockers, and thiazide or thiazide-like diuretics are
effective in reducing cardiovascular events in patients with
hypertension associated with chronic kidney disease (16,17).
However, angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers are more effective than other
antihypertensive drugs in slowing progression of chronic
kidney disease with proteinuria (18,19). The combined
use of an angiotensin-converting enzyme inhibitor with an
angiotensin receptor blocker should be avoided (20).
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